VEGFA and nonpapillary renal cell carcinoma: It is approved for use in ccRCC patients after progression on an immune checkpoint inhibitor and VEGF inhibitor, and in VHL disease patients with ccRCC, CNS hemangioblastomas, or PNETs not requiring immediate surgery; it is currently being investigated in the front-line setting.